Iptakalim attenuates hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection

Zhu,Rong; Bi,Li‑Qing; Wu,Su‑Ling; Li,Lan; Kong,Hui; Xie,Wei-Ping; Wang,Hong; Meng,Zi-Li

doi:10.3892/mmr.2015.3695

Iptakalim attenuates hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection

Authors:
- Rong Zhu
- Li‑Qing Bi
- Su‑Ling Wu
- Lan Li
- Hui Kong
- Wei-Ping Xie
- Hong Wang
- Zi-Li Meng
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Geriatric Intensive Care Unit, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Respiratory Medicine, The Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: April 28, 2015 https://doi.org/10.3892/mmr.2015.3695
Pages: 2945-2952

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the protective effects of iptakalim, an adenosine triphosphate (ATP)-sensitive potassium channel opener, on the inflammation of the pulmonary artery and endothelial cell injury in a hypoxia‑induced pulmonary arterial hypertension (PAH) rat model. Ninety‑six Sprague‑Dawley rats were placed into normobaric hypoxia chambers for four weeks and were treated with iptakalim (1.5 mg/kg/day) or saline for 28 days. The right ventricle systolic pressures (RVSP) were measured and small pulmonary arterial morphological alterations were analyzed with hematoxylin and eosin staining. Enzyme‑linked immunosorbent assay (ELISA) was performed to analyze the content of interleukin (IL)‑1β and IL‑10. Immunohistochemical analysis for ED1+ monocytes was performed to detect the inflammatory cells surrounding the pulmonary arterioles. Western blot analysis was performed to analyze the expression levels of platelet endothelial cell adhesion molecule‑1 (PECAM‑1) and endothelial nitric oxide synthase (eNOS) in the lung tissue. Alterations in small pulmonary arteriole morphology and the ultrastructure of pulmonary arterial endothelial cells were observed via light and transmission electron microscopy, respectively. Iptakalim significantly attenuated the increase in mean pulmonary artery pressure, RVSP, right ventricle to left ventricle plus septum ratio and small pulmonary artery wall remodeling in hypoxia‑induced PAH rats. Iptakalim also prevented an increase in IL‑1β and a decrease in IL‑10 in the peripheral blood and lung tissue, and alleviated inflammatory cell infiltration in hypoxia‑induced PAH rats. Furthermore, iptakalim enhanced PECAM‑1 and eNOS expression and prevented the endothelial cell injury induced by hypoxic stimuli. Iptakalim suppressed the pulmonary arteriole and systemic inflammatory responses and protected against the endothelial damage associated with the upregulation of PECAM‑1 and eNOS, suggesting that iptakalim may represent a potential therapeutic agent for PAH.

View Figures

View References

1	Archer S and Rich S: Primary pulmonary hypertension: a vascular biology and translational research ‘Work in progress’. Circulation. 102:2781–2791. 2000. View Article : Google Scholar : PubMed/NCBI
2	Humbert M, Sitbon O and Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 351:1425–1436. 2004. View Article : Google Scholar : PubMed/NCBI
3	Böhm F and Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 76:8–18. 2007. View Article : Google Scholar : PubMed/NCBI
4	Csiszar A, Labinskyy N, Olson S, et al: Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 54:668–675. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hironaka E, Hongo M, Sakai A, et al: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 60:692–699. 2003. View Article : Google Scholar : PubMed/NCBI
6	Firth AL, Mandel J and Yuan JX: Idiopathic pulmonary arterial hypertension. Dis Model Mech. 3:268–273. 2010. View Article : Google Scholar : PubMed/NCBI
7	Voelkel NF and Cool C: Pathology of pulmonary hypertension. Cardiol Clin. 22:343–351. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhang B, Luo Y, Liu ML, et al: Macrophage migration inhibitory factor contributes to hypoxic pulmonary vasoconstriction in rats. Microvasc Res. 83:205–212. 2012. View Article : Google Scholar
9	McNicholas WT: Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 180:692–700. 2009. View Article : Google Scholar : PubMed/NCBI
10	Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S and Eddahibi S: Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 10:62009. View Article : Google Scholar : PubMed/NCBI
11	Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C and Johns RA: Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J Immunol. 185:5539–5548. 2010. View Article : Google Scholar : PubMed/NCBI
12	Vergadi E, Chang MS, Lee C, et al: Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 123:1986–1995. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wang H: Pharmacological characteristics of the novel antihypertensive drug iptakalim hydrochloride and its molecular mechanisms. Drug Development Research. 58:65–68. 2003. View Article : Google Scholar
14	Zhou F, Wu JY, Sun XL, Yao HH, Ding JH and Hu G: Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology. 32:2570–2580. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wang H, Long C, Duan Z, Shi C, Jia G and Zhang Y: A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res. 73:497–503. 2007. View Article : Google Scholar
16	Gao S, Long CL, Wang RH and Wang H: K_(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 83:444–456. 2009. View Article : Google Scholar : PubMed/NCBI
17	Xie W, Wang H, Wang H and Hu G: Effects of iptakalim hydrochloride, a novel K_ATP channel opener, on pulmonary vascular remodeling in hypoxic rats. Life Sciences. 75:2065–2076. 2004. View Article : Google Scholar
18	Everett AD, Le Cras TD, Xue C and Johns RA: eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol. 274:L1058–L1065. 1998.PubMed/NCBI
19	Megalou AJ, Glava C, Oikonomidis DL, et al: Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats. J Clin Exp Med. 3:332–340. 2010.
20	Qi X, Xie WP, Wang H and Hu G: Changes of pulmonary arterial endothelial cells in chronic hypoxic rats and intervention of iptakalim hydrochloride. Zhongguo Linchuang Kangfu Zazhi. 9:94–96. 2005.In Chinese.
21	Rabinovitch M, Gamble W, Nadas AS, Miettinen OS and Reid L: Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol. 236:H818–H827. 1979.PubMed/NCBI
22	Dorfmüller P, Perros F, Balabanian K and Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J. 22:358–363. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M and Mouthon L: The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 44:31–38. 2013. View Article : Google Scholar
24	Humbert M, Monti G, Brenot F, et al: Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 151:1628–1631. 1995. View Article : Google Scholar : PubMed/NCBI
25	Tsai BM, Wang M, Pitcher JM, Kher A, Crisostomo P and Meldrum DR: Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock. 24:417–420. 2005. View Article : Google Scholar : PubMed/NCBI
26	Nonaka-Sarukawa M, Okada T, Ito T, et al: Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. J Gene Med. 10:368–374. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ito T and Ikeda U: Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy. 2:257–265. 2003. View Article : Google Scholar : PubMed/NCBI
28	Chen S, Kapturczak MH, Wasserfall C, et al: Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway. Proc Natl Acad Sci USA. 102:7251–7256. 2005. View Article : Google Scholar : PubMed/NCBI
29	Mazighi M, Pellé A, Gonzalez W, et al: IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol. 287:H866–H871. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ito T, Okada T, Miyashita H, et al: Interleukin-10 expression mediated by an adeno-associated virus vector prevents mono-crotaline-induced pulmonary arterial hypertension in rats. Circ Res. 101:734–741. 2007. View Article : Google Scholar : PubMed/NCBI
31	Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J and McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 143:4828–4836. 2002. View Article : Google Scholar : PubMed/NCBI
32	Sprague AH and Khalil RA: Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 78:539–552. 2009. View Article : Google Scholar : PubMed/NCBI
33	Alan B and Nalbantgil S: Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension. Anadolu Kardiyol Derg. 1:9–13. 2010. View Article : Google Scholar
34	Bauersachs J and Widder JD: Endothelial dysfunction in heart failure. Pharmacol Rep. 60:119–126. 2008.PubMed/NCBI
35	Janigro D, West GA, Gordon EL, et al: ATP-sensitive K⁺ channels in rat aorta and brain microvascular endothelial cells. Am J Physiol. 265:C812–C821. 1993.PubMed/NCBI
36	Newman PJ: The biology of PECAM-1. J Clin Invest. 100:S25–S29. 1997.PubMed/NCBI
37	DeLisser HM, Helmke BP, Cao G, et al: Loss of PECAM-1 function impairs alveolarization. J Biol Chem. 281:8724–8731. 2006. View Article : Google Scholar
38	Goel R, Boylan B, Gruman L, North PE and Newman DK: The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 293:G1205–G1214. 2007. View Article : Google Scholar : PubMed/NCBI
39	Woodfin A, Viosin MB and Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 27:G2514–G2523. 2007. View Article : Google Scholar
40	Goel R, Boylan B, Gruman L, Newman PJ, North PE and Newman DK: The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 293:1205–1214. 2007. View Article : Google Scholar
41	Ikarashi N, Toba K, Kato K, et al: Erythropoietin, but not asialoerythropoietin or carbamyl-erythropoietin, attenuates monocrotaline-induced pulmonary hypertension in rats. Clin Exp Hypertens. 34:575–581. 2012. View Article : Google Scholar : PubMed/NCBI
42	Chen K and Popel AS: Theoretical analysis of biochemical pathways of nitric oxide release from vascular endothelial cells. Free Radic Biol Med. 41:668–680. 2006. View Article : Google Scholar : PubMed/NCBI